[{"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-001", "question": "A 52-year-old man with primary sclerosing cholangitis and ulcerative colitis maintained on vedolizumab presents with progressive jaundice, pruritus, and weight loss over 3 months. MRCP shows a dominant stricture at the hepatic hilum with intrahepatic ductal dilation. CA 19-9 is 180 U/mL. Brush cytology from ERCP is suspicious but not diagnostic for malignancy. PET-CT shows FDG avidity at the stricture with standardized uptake value (SUV) max of 6.2. Which of the following is the most appropriate next step in management?", "options": ["Proceed directly to liver transplantation without biopsy confirmation given high suspicion for cholangiocarcinoma in PSC", "Perform endoscopic ultrasound with fine-needle aspiration of the hilar mass", "Initiate neoadjuvant chemoradiation followed by liver transplantation per Mayo Clinic protocol", "Repeat ERCP with cholangioscopy and targeted biopsies of the suspicious area", "Treat as benign dominant stricture with serial stenting and repeat CA 19-9 in 3 months"], "answer": "C", "answer_index": 2, "explanation": "In patients with PSC and suspected hilar cholangiocarcinoma, the Mayo Clinic protocol for neoadjuvant chemoradiation followed by liver transplantation requires strict diagnostic criteria including biopsy confirmation or strongly suggestive findings (CA 19-9 >100 U/mL, malignant-appearing stricture on imaging). PET SUV >5.0 with suspicious cytology meets criteria for protocol enrollment. Direct transplantation without protocol adherence risks transplanting unrecognized metastatic disease. Cholangioscopy and EUS-FNA have higher risks of peritoneal seeding in potentially resectable/transplantable cases.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: U. Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the most appropriate next step for a PSC patient with suspected hilar cholangiocarcinoma based on progressive symptoms, imaging, elevated CA 19-9, suspicious cytology, and FDG-avid stricture. Key stem clues: PSC history, jaundice/pruritus/weight loss, hilar stricture with dilation on MRCP, CA 19-9 180 U/mL, suspicious cytology, PET SUV max 6.2; no mention of lesion size, mass presence, FISH results, or explicit absence of metastases. Likely diagnosis: cholangiocarcinoma in PSC. Keyed answer C fits if assuming Mayo protocol eligibility (e.g., lesion <3 cm, no mets), allowing neoadjuvant chemoradiation then transplant. Alternatives: A risks transplanting malignancy without neoadjuvant; B risks peritoneal seeding via FNA; D offers diagnostic confirmation via cholangioscopy but may be unnecessary if criteria met; E ignores high suspicion. Main logical issue: underspecified, missing critical details like lesion size/mass dimensions required for protocol eligibility, necessitating unstated assumptions for unique best (C). Main medical accuracy issues: overemphasizes PET SUV >5 as diagnostic criterion (not standard in Mayo protocol); inaccurately equates cholangioscopy seeding risk with EUS-FNA (cholangioscopy is intraductal with lower risk). Minimal fix: Add to stem 'MRCP shows a 2.5 cm hilar mass' to confirm protocol suitability and eliminate underspecification.\",\n  \"medical_accuracy_score\": 3,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"U\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: U. Verdict on keyed answer: Not uniquely determinable. The clinical problem is determining the most appropriate next step for a PSC patient with suspected hilar cholangiocarcinoma based on progressive symptoms, imaging, elevated CA 19-9, suspicious cytology, and FDG-avid stricture. Key stem clues: PSC history, jaundice/pruritus/weight loss, hilar stricture with dilation on MRCP, CA 19-9 180 U/mL, suspicious cytology, PET SUV max 6.2; no mention of lesion size, mass presence, FISH results, or explicit absence of metastases. Likely diagnosis: cholangiocarcinoma in PSC. Keyed answer C fits if assuming Mayo protocol eligibility (e.g., lesion <3 cm, no mets), allowing neoadjuvant chemoradiation then transplant. Alternatives: A risks transplanting malignancy without neoadjuvant; B risks peritoneal seeding via FNA; D offers diagnostic confirmation via cholangioscopy but may be unnecessary if criteria met; E ignores high suspicion. Main logical issue: underspecified, missing critical details like lesion size/mass dimensions required for protocol eligibility, necessitating unstated assumptions for unique best (C). Main medical accuracy issues: overemphasizes PET SUV >5 as diagnostic criterion (not standard in Mayo protocol); inaccurately equates cholangioscopy seeding risk with EUS-FNA (cholangioscopy is intraductal with lower risk). Minimal fix: Add to stem 'MRCP shows a 2.5 cm hilar mass' to confirm protocol suitability and eliminate underspecification.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "U", "verdict": "FAIL", "fail_reason": "U"}, "judge_verdict": "FAIL", "judge_fail_reason": "U", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-002", "question": "A 38-year-old woman with paroxysmal nocturnal hemoglobinuria (PNH) on eculizumab for 5 years presents with fatigue and dark urine. Laboratory studies show hemoglobin 7.2 g/dL (baseline 10.5), LDH 850 U/L (baseline 300), haptoglobin <10 mg/dL, and negative direct antiglobulin test. She received her last eculizumab dose 12 days ago. Peripheral blood flow cytometry shows 95% PNH clone size (granulocytes). Complement C5 level is undetectable. Which of the following is the most likely explanation for her breakthrough hemolysis?", "options": ["Development of anti-eculizumab antibodies causing drug neutralization", "C5 gene polymorphism (c.2654G→A) resulting in eculizumab-resistant C5", "Concurrent mycoplasma pneumoniae infection with cold agglutinin production", "Functional deficiency of complement factor H due to acquired mutation", "Proximal complement pathway activation via C3 convertase amplification"], "answer": "B", "answer_index": 1, "explanation": "The c.2654G→A polymorphism in the C5 gene results in a single amino acid change (p.Arg885His) that prevents eculizumab binding while maintaining C5 function, leading to breakthrough hemolysis despite adequate drug levels. This autosomal dominant mutation affects approximately 3-4% of Japanese patients and requires switching to ravulizumab or other anti-C5 agents. Anti-drug antibodies are rare with eculizumab. Mycoplasma would cause cold agglutinin disease with positive DAT. Factor H deficiency causes atypical HUS, not PNH exacerbation.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: C (primary; secondary U leading to N). Verdict on keyed answer: Not uniquely determinable (item incoherent, no defensible answer). Key stem clues: Paroxysmal nocturnal hemoglobinuria on eculizumab, breakthrough symptoms (fatigue, dark urine), labs indicating intravascular hemolysis (Hb 7.2 g/dL, LDH 850 U/L, haptoglobin <10 mg/dL, negative DAT), last dose 12 days ago, 95% PNH clone, undetectable C5 level – these drive toward a cause of hemolysis despite apparent C5 blockade but create inconsistency. Main logical issue(s): Internal contradiction (C) as undetectable C5 implies complete terminal complement inhibition, precluding MAC-mediated intravascular hemolysis in PNH, making the clinical presentation incoherent/unsolvable; underspecified (U) without trigger for breakthrough (e.g., infection), leading to no defensible answer (N). Main medical accuracy issue(s): Keyed answer B is medically valid as a real cause (C5 polymorphism causes eculizumab resistance, prevalent in some populations), but vignette inaccurately pairs it with undetectable C5 – in reality, the variant results in residual detectable C5 activity/ incomplete inhibition; rationale correctly notes rarity of anti-drug antibodies and DAT positivity in cold agglutinin, but item misrepresents lab correlation. Minimal fix: Revise stem to 'residual complement C5 activity detected despite therapeutic eculizumab levels' to align with B and resolve contradiction.\",\n  \"medical_accuracy_score\": 2,\n  \"logical_validity\": false,\n  \"logical_false_reason\": \"C\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: C (primary; secondary U leading to N). Verdict on keyed answer: Not uniquely determinable (item incoherent, no defensible answer). Key stem clues: Paroxysmal nocturnal hemoglobinuria on eculizumab, breakthrough symptoms (fatigue, dark urine), labs indicating intravascular hemolysis (Hb 7.2 g/dL, LDH 850 U/L, haptoglobin <10 mg/dL, negative DAT), last dose 12 days ago, 95% PNH clone, undetectable C5 level – these drive toward a cause of hemolysis despite apparent C5 blockade but create inconsistency. Main logical issue(s): Internal contradiction (C) as undetectable C5 implies complete terminal complement inhibition, precluding MAC-mediated intravascular hemolysis in PNH, making the clinical presentation incoherent/unsolvable; underspecified (U) without trigger for breakthrough (e.g., infection), leading to no defensible answer (N). Main medical accuracy issue(s): Keyed answer B is medically valid as a real cause (C5 polymorphism causes eculizumab resistance, prevalent in some populations), but vignette inaccurately pairs it with undetectable C5 – in reality, the variant results in residual detectable C5 activity/ incomplete inhibition; rationale correctly notes rarity of anti-drug antibodies and DAT positivity in cold agglutinin, but item misrepresents lab correlation. Minimal fix: Revise stem to 'residual complement C5 activity detected despite therapeutic eculizumab levels' to align with B and resolve contradiction.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-003", "question": "A 67-year-old man who underwent orthotopic liver transplantation 4 months ago for HCV cirrhosis presents with fever, cough, and hypoxemia. He is on tacrolimus and prednisone 5 mg daily. Chest CT shows multiple nodular opacities with surrounding ground-glass halos. Bronchoalveolar lavage PCR is positive for Torque teno virus (TTV) DNA at 10^8 copies/mL. Blood TTV viral load is 10^7 copies/mL. Which of the following is the most appropriate interpretation and management?", "options": ["TTV indicates severe immunosuppression; reduce tacrolimus dose and monitor for resolution", "TTV is a direct pulmonary pathogen; initiate intravenous ribavirin therapy", "TTV reactivation suggests CMV co-infection; start ganciclovir empirically", "TTV viral load has no clinical significance in this setting; pursue alternative diagnoses", "TTV indicates possible donor-derived infection; perform lung biopsy for histopathology"], "answer": "A", "answer_index": 0, "explanation": "Torque teno virus (TTV) viral load serves as a functional biomarker of overall immunosuppression in transplant recipients, with high levels indicating excessive immunosuppression and increased risk of opportunistic infections. The radiographic findings suggest invasive fungal infection (e.g., aspergillosis) in an over-immunosuppressed host. Reducing immunosuppression while evaluating for fungal pathogens is appropriate. TTV itself is not a pulmonary pathogen. There is no established antiviral therapy for TTV, and it does not specifically indicate CMV co-infection or donor-derived infection.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Post-liver transplant patient on tacrolimus and low-dose prednisone presenting with fever, cough, hypoxemia; CT showing nodular opacities with ground-glass halos (suggestive of invasive fungal infection like aspergillosis); high TTV viral loads in BAL (10^8 copies/mL) and blood (10^7 copies/mL), indicating excessive immunosuppression as a biomarker. These clues point to over-immunosuppression increasing opportunistic infection risk, making reduction of tacrolimus (option A) the most appropriate management to restore immune balance while monitoring. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., high TTV loads, classic CT findings) to support A as uniquely best without contradictions or underspecification. Alternatives are inferior: B assumes TTV pathogenicity (incorrect); C links to CMV without evidence; D dismisses TTV's biomarker role; E presumes donor origin unnecessarily. Main medical accuracy issue(s): None; aligns with emerging evidence on TTV as an immunosuppression biomarker in transplants, where high loads correlate with infection risk, and reducing immunosuppression is standard for suspected over-suppression in this context. CT findings accurately reflect fungal patterns in immunocompromised hosts. Minimal fix: None needed; item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: Post-liver transplant patient on tacrolimus and low-dose prednisone presenting with fever, cough, hypoxemia; CT showing nodular opacities with ground-glass halos (suggestive of invasive fungal infection like aspergillosis); high TTV viral loads in BAL (10^8 copies/mL) and blood (10^7 copies/mL), indicating excessive immunosuppression as a biomarker. These clues point to over-immunosuppression increasing opportunistic infection risk, making reduction of tacrolimus (option A) the most appropriate management to restore immune balance while monitoring. Main logical issue(s): None; the stem provides sufficient discriminating details (e.g., high TTV loads, classic CT findings) to support A as uniquely best without contradictions or underspecification. Alternatives are inferior: B assumes TTV pathogenicity (incorrect); C links to CMV without evidence; D dismisses TTV's biomarker role; E presumes donor origin unnecessarily. Main medical accuracy issue(s): None; aligns with emerging evidence on TTV as an immunosuppression biomarker in transplants, where high loads correlate with infection risk, and reducing immunosuppression is standard for suspected over-suppression in this context. CT findings accurately reflect fungal patterns in immunocompromised hosts. Minimal fix: None needed; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-004", "question": "A 44-year-old woman with autoimmune hepatitis-primary biliary cholangitis overlap syndrome on ursodeoxycholic acid and budesonide develops recurrent episodes of severe, cramping abdominal pain with diarrhea occurring 30-60 minutes after meals. Symptoms improve with fasting. CT angiography shows no mesenteric ischemia. Gastric emptying study is normal. Upper endoscopy with duodenal biopsies shows villous blunting and intraepithelial lymphocytes. Serum tryptase during an episode is 45 ng/mL (normal <11.4). Which of the following is the most likely diagnosis?", "options": ["Mesenteric venous thrombosis with portal hypertensive enteropathy", "Systemic mastocytosis with gastrointestinal involvement", "Celiac disease with refractory sprue", "Abdominal angina from median arcuate ligament syndrome", "Bile acid malabsorption due to ileal dysfunction"], "answer": "B", "answer_index": 1, "explanation": "Systemic mastocytosis can present with postprandial abdominal pain, diarrhea, and flushing due to mast cell mediator release triggered by food. Elevated serum tryptase (>20 ng/mL) during symptoms is diagnostic. The duodenal findings represent mast cell infiltration rather than celiac disease. Mesenteric ischemia was ruled out by CT angiography. Median arcuate ligament syndrome causes epigastric pain but not diarrhea or elevated tryptase. Bile acid malabsorption does not explain the elevated tryptase or timing of symptoms.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Gastrointestinal", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postprandial cramping abdominal pain and diarrhea improving with fasting, villous blunting with intraepithelial lymphocytes on duodenal biopsy, markedly elevated serum tryptase (45 ng/mL) during symptoms, negative CT angiography for ischemia, normal gastric emptying, and background of autoimmune hepatitis-PBC overlap on UDCA and budesonide. These clues point to mast cell mediator release triggered by meals, with tryptase elevation diagnostic for systemic mastocytosis (B), while duodenal changes reflect mast cell infiltration mimicking celiac-like enteropathy. No main logical issues; the stem provides sufficient discriminating details without contradictions, allowing B as the single best option. Alternatives are inferior: A lacks thrombosis evidence; C fits biopsy but not tryptase or symptom timing without gluten context; D causes pain without diarrhea/tryptase rise; E explains diarrhea but not pain, tryptase, or biopsy. No medical accuracy issues; aligns with current standards where tryptase >20 ng/mL supports mastocytosis diagnosis, GI symptoms from mediator release are classic, and mimics like celiac are recognized. Minimal fix: None needed, as item is already unambiguous and accurate.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include postprandial cramping abdominal pain and diarrhea improving with fasting, villous blunting with intraepithelial lymphocytes on duodenal biopsy, markedly elevated serum tryptase (45 ng/mL) during symptoms, negative CT angiography for ischemia, normal gastric emptying, and background of autoimmune hepatitis-PBC overlap on UDCA and budesonide. These clues point to mast cell mediator release triggered by meals, with tryptase elevation diagnostic for systemic mastocytosis (B), while duodenal changes reflect mast cell infiltration mimicking celiac-like enteropathy. No main logical issues; the stem provides sufficient discriminating details without contradictions, allowing B as the single best option. Alternatives are inferior: A lacks thrombosis evidence; C fits biopsy but not tryptase or symptom timing without gluten context; D causes pain without diarrhea/tryptase rise; E explains diarrhea but not pain, tryptase, or biopsy. No medical accuracy issues; aligns with current standards where tryptase >20 ng/mL supports mastocytosis diagnosis, GI symptoms from mediator release are classic, and mimics like celiac are recognized. Minimal fix: None needed, as item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-005", "question": "A 62-year-old man with essential thrombocythemia (JAK2 V617F-positive) on hydroxyurea presents with acute onset of severe headache and right hemiparesis. CT head shows left middle cerebral artery territory infarction. Platelet count is 450,000/μL. MRI brain with contrast reveals multiple small enhancing lesions in both cerebral hemispheres. Transthoracic echocardiogram shows no vegetations. Blood cultures are negative. Which of the following is the most likely underlying mechanism for his stroke?", "options": ["Nonbacterial thrombotic endocarditis from hypercoagulable state", "Leukoencephalopathy from hydroxyurea toxicity", "Transformation to acute myeloid leukemia with CNS involvement", "Cerebral vasculitis secondary to JAK2 mutation", "Paradoxical embolism through patent foramen ovale"], "answer": "A", "answer_index": 0, "explanation": "Myeloproliferative neoplasms, particularly essential thrombocythemia, can cause nonbacterial thrombotic endocarditis (NBTE) with sterile vegetations that embolize to cerebral arteries. The multiple enhancing brain lesions represent septic emboli analogs from NBTE. Hydroxyurea leukoencephalopathy causes symmetric white matter changes without enhancing lesions. AML transformation would show blasts in blood or marrow. Cerebral vasculitis is not associated with JAK2 mutations. Paradoxical embolism would not explain multiple enhancing lesions without a venous source.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Hematology", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: ET with JAK2 mutation (hypercoagulable MPN), acute MCA infarct, multiple small bilateral enhancing brain lesions on MRI (suggesting embolic source), TTE negative for vegetations (possible miss in NBTE), negative blood cultures (rules out infection), controlled platelets on hydroxyurea. These point to embolic mechanism from sterile vegetations in NBTE, fitting A. Main logical issue(s), if any: None; stem allows discrimination of A as uniquely best without contradictions or underspecification, as alternatives are clearly inferior based on vignette details (e.g., no blasts for C, no PFO/venous source for E). Main medical accuracy issue(s), if any: Mostly consistent with standards—NBTE is associated with MPNs like ET causing embolic strokes; however, hydroxyurea is not typically linked to leukoencephalopathy (B is a weak distractor, possibly inaccurate as a concept), and enhancing lesions in NBTE are plausible but not classically emphasized (could represent subacute infarcts). Item aligns with board-level knowledge on hypercoagulability in MPNs. Minimal fix: None required; item is unambiguous and accurate as is.\",\n  \"medical_accuracy_score\": 4,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer: ET with JAK2 mutation (hypercoagulable MPN), acute MCA infarct, multiple small bilateral enhancing brain lesions on MRI (suggesting embolic source), TTE negative for vegetations (possible miss in NBTE), negative blood cultures (rules out infection), controlled platelets on hydroxyurea. These point to embolic mechanism from sterile vegetations in NBTE, fitting A. Main logical issue(s), if any: None; stem allows discrimination of A as uniquely best without contradictions or underspecification, as alternatives are clearly inferior based on vignette details (e.g., no blasts for C, no PFO/venous source for E). Main medical accuracy issue(s), if any: Mostly consistent with standards—NBTE is associated with MPNs like ET causing embolic strokes; however, hydroxyurea is not typically linked to leukoencephalopathy (B is a weak distractor, possibly inaccurate as a concept), and enhancing lesions in NBTE are plausible but not classically emphasized (could represent subacute infarcts). Item aligns with board-level knowledge on hypercoagulability in MPNs. Minimal fix: None required; item is unambiguous and accurate as is.", "medical_accuracy_score": 4, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251219T221819110Z_deepseek-v3.2_seed133", "question_id": "20251219T221819110Z_deepseek-v3.2_seed133-006", "question": "A 31-year-old hematopoietic stem cell transplant recipient (day +45) for AML develops new-onset confusion and myoclonus. MRI brain shows symmetric T2 hyperintensities in the thalami and periaqueductal gray matter. CSF shows 5 WBCs/μL, protein 65 mg/dL, glucose 60 mg/dL (serum 95 mg/dL). CSF PCR for HSV, VZV, EBV, CMV, and HHV-6 are negative. Metagenomic next-generation sequencing of CSF detects Astrovirus VA1/HMO-C RNA. Which of the following is the most appropriate management?", "options": ["Intravenous immunoglobulin 2 g/kg divided over 2-5 days", "Oral nitazoxanide 500 mg twice daily for 14 days", "Reduce immunosuppression and provide supportive care", "Intravenous ribavirin loading dose 33 mg/kg then 16 mg/kg every 6 hours", "Intrathecal administration of foscarnet 40 mg twice weekly"], "answer": "C", "answer_index": 2, "explanation": "Astrovirus VA1/HMO-C encephalitis in immunocompromised hosts has no proven antiviral therapy. Reduction of immunosuppression to allow immune reconstitution is the mainstay of management, along with supportive care. Intravenous immunoglobulin has been used but lacks proven efficacy. Nitazoxanide has in vitro activity but no clinical data in CNS infections. Ribavirin has poor CNS penetration and no proven benefit. Intrathecal foscarnet is used for HSV/VZV encephalitis but not for astrovirus.", "generator_model": "deepseek-v3.2", "seed": 133, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "target_topic": "Infectious Disease", "judge_model": "grok-4-0709", "judge_model_outputs_raw": "{\n  \"analysis\": \"Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-HSCT immunocompromised state (day +45), acute confusion and myoclonus, symmetric thalamic and periaqueductal T2 hyperintensities on MRI, mild CSF pleocytosis with elevated protein and normal glucose, negative PCR for common herpesviruses, and positive metagenomic NGS for Astrovirus VA1/HMO-C RNA. These point to astrovirus encephalitis without alternative diagnoses, making reduction of immunosuppression and supportive care the standard management due to lack of proven antivirals. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., specific pathogen detection, exclusion of common viruses) to identify C as uniquely best, with alternatives lacking evidence or applicability. Main medical accuracy issue(s): none; aligns with current consensus that astrovirus CNS infections in immunocompromised hosts have no established antiviral therapy, emphasizing immune reconstitution per transplant guidelines (e.g., similar to other opportunistic infections like PML). The rationale correctly notes limitations of options like ribavirin’s poor CNS penetration and absence of data for nitazoxanide in CNS. Minimal fix: none needed; item is unambiguous and accurate as written.\",\n  \"medical_accuracy_score\": 5,\n  \"logical_validity\": true,\n  \"logical_false_reason\": \"T\"\n}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict on keyed answer: Correct best. Key stem clues that drive a unique best answer include post-HSCT immunocompromised state (day +45), acute confusion and myoclonus, symmetric thalamic and periaqueductal T2 hyperintensities on MRI, mild CSF pleocytosis with elevated protein and normal glucose, negative PCR for common herpesviruses, and positive metagenomic NGS for Astrovirus VA1/HMO-C RNA. These point to astrovirus encephalitis without alternative diagnoses, making reduction of immunosuppression and supportive care the standard management due to lack of proven antivirals. Main logical issue(s): none; the stem provides sufficient discriminating details (e.g., specific pathogen detection, exclusion of common viruses) to identify C as uniquely best, with alternatives lacking evidence or applicability. Main medical accuracy issue(s): none; aligns with current consensus that astrovirus CNS infections in immunocompromised hosts have no established antiviral therapy, emphasizing immune reconstitution per transplant guidelines (e.g., similar to other opportunistic infections like PML). The rationale correctly notes limitations of options like ribavirin’s poor CNS penetration and absence of data for nitazoxanide in CNS. Minimal fix: none needed; item is unambiguous and accurate as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]